Atlas Trials

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Clinical trial NCT04323956 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04323956
Sponsor
Mayo Clinic
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Ann Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaDiffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Start date
2020-06-15
Primary completion
2023-10-04
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.